Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 120Observational 7Expanded_access 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

PSR Ovarian Cancer With a BRCA Mutation 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

olaparib 2ulixertinib 1selinexor 1pegilodecakin 1niraparib 1balstilimab 1Proton Pump Inhibitors 1Hydrocortisone 1FANG vaccine 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × olaparib × Gynecologic × Clear all
NCT03063710 2018-05-17

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

AstraZeneca

No longer available
Gynecologic

PSR Ovarian Cancer With a BRCA Mutation

NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AstraZeneca

Approved for marketing
Gynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡